Mohamed Hegazi

Frontline AML in 2026: target early, measure deeply, and rethink "fit." Highlights from Dr. Nicholas Short's @NicholasShortMD @UTMDAnderson (MD Anderson) talk at the 4th Louisville Hematology Highlights: 🎯 FLT3 • Quizartinib generally preferred over midostaurin with 7+3, unless QTc is an issue • HOVON 156: gilteritinib beat midostaurin on RFS, not OS • MORPHO: post-transplant gilteritinib benefit concentrated in MRD+ patients 🔬 MRD • NPM1 + FLT3-ITD with deep MRD clearance: CR1 transplant is now a discussion, not a reflex 💊 Venetoclax + intensive chemo • FLAG-IDA or CLIA + only 7 days of ven: CRc 95%, ~57% long-term survival even in ELN adverse risk ⚖️ PARADIGM • Aza-ven vs intensive chemo in fit, mostly adverse-risk adults: more patients to transplant, lower 60-day mortality, better QoL, better EFS. No OS difference. 🧬 Triplets • Aza-ven-gilteritinib: CR 90%, 3-yr OS 46%, median age 71 • HMA-ven + IDH inhibitor: CRc 92% • Aza-ven-revumenib: ~90% remission in KMT2A-r, but early deaths in NPM1 mean dosing still needs work • Doublets: 28 days of ven still beats 14 (driven by NPM1 and IDH2) Still unmet: TP53, MECOM, RAS-pathway AML, and a mutation-agnostic third agent. Thank you Dr. Short for a superb talk 👏 #AML #leusm #MedTwitter #Hematology youtu.be/Ah1ocXpWkVY?is=mz8z…

My #ASH26 sneak peek from the 4th Louisville Hematology Highlights: 60 abstracts, 12 disease states, one pick per drug, ranked by design, size and effect. 46 orals, incl. 1 plenary. Highlights below 🧵 ⭐️Myeloma, phase 3: • MonumenTAL-6: Tec + Tal vs EPd/PVd, PFS HR 0.11, OS HR 0.38 • MagnetisMM-5: elranatamab beats DPd on PFS (n=497) • EXCALIBER: iberdomide-Dd vs DVd, PFS HR 0.49, MRD-neg CR 41% vs 21% #mmsm ⭐️Myeloma, next wave: • Trispecific ramantamig + Dara-Len in transplant-eligible NDMM: ≥CR 81%, 20/20 MRD-neg, no ICANS • ISB 2001 (CD38×BCMA×CD3): ORR 75–85%, no grade ≥3 CRS • CARTITUDE-4: first OS data in dara-refractory pts #mmsm ⭐️AML: menin inhibitors move up front • Ziftomenib + 7+3 + quizartinib: CRc 100% at both doses, no DLTs • Aza/ven/revumenib, final ph1b • Bleximenib, ph2 in R/R • Revumenib maintenance after allo-HCT #leusm ⭐️MRD before transplant: whole-genome MRD in AML (MEASURE, 18 US centers) had 97% sensitivity vs 31% by flow. MRD+ pts: relapse HR 7.5. B-ALL (E1910, ph3): blinatumomab improves OS even in NGS MRD-negative pts. #leusm #bmtsm ⭐️ Lymphoma: • Plenary: MANGROVE, zanubrutinib-R vs BR in untreated MCL, PFS HR 0.57 • R-GemOx is the comparator to beat in R/R DLBCL: LOTIS-5, EPCORE DLBCL-4 (PFS HR 0.40), STARGLO at 4 yrs, SUNMO at 3 yrs #lymsm ⭐️ CAR-T is changing shape: • Ronde-cel (CD19/CD20): ORR 91%, 75% still in CR at 12 mo, no grade ≥3 CRS • In vivo CAR-T, no ex vivo manufacturing: LB2501, UB-VV400 • Brexu-cel as consolidation in high-risk B-ALL #CARTcell ⭐️ CLL & indolent: • Sonrotoclax + zanubrutinib: 99% uMRD4 at ~40 mo • Glofitamab ± pola in Richter's • Lonca in R/R MZL: ORR 93%, 2-yr PFS 91% • Chemo-free frontline FL: golcadomide-R, mosun-pola #lymsm #leusm ⭐️ MPN & MDS: • PV: divesiran kept Hct <45% without phlebotomy, 88% vs 19% • MF: first mutant-CALR antibody; anti-hemojuvelin for anemia • ET: first CALRmut×CD3 T-cell engager • MDS: all-oral aza/cedazuridine #MPNsm #MDSsm ⭐️Transplant & classical heme: • Reduced-dose PTCy, MMUD HCT: 1-yr OS 88.7% • Weekly rezafungin non-inferior to standard prophylaxis, less AKI • Sickle cell: HDR correction and base editing • BCMA×CD3 in ITP/AIHA: 18/20 and 9/9 responses #bmtsm ⭐️ASH 2026 · New Orleans · Dec 12–15 Late-breaking abstracts online Dec 7. Which abstract is top of your list? #ASH26

During our annual Louisville Hematology Highlights, we managed to get a photo with BCT’s MDs, APPs and PharmDs. Missing som! @UofLMedicine @UofLHealth #LHH26

It was great having @Ramikomrokji @catmariebyrne show case a day in an expert MDS clinic an MD and APP perspectives.

4th Louisville Hematology Highlights 🩸 📅 This Saturday, Nov 7 | Louisville, KY A full day of leukemia, lymphoma, MDS, myeloma & cellular therapy updates from MD Anderson, NYU Langone, WashU, UTSW, MCW, Moffitt, MSK, Sarah Cannon & UNMC faculty, plus a nursing program. Main program: • Welcome & ASH 2026 Sneak Peek: me • ALL: Hagop Kantarjian (MD Anderson) • Aggressive lymphoma: John Leonard (NYU Langone) & Nancy Bartlett (WashU) • Indolent lymphoma: Farrukh Awan (UTSW) & Mehdi Hamadani (MCW) • AML: Nicholas Short (MD Anderson) • MDS: Rami Komrokji & Catherine Byrne (Moffitt) • Myeloma: Hamza Hashmi (MSK) & Hans Lee (Sarah Cannon) • Herzig Memorial Lecture, Cellular Therapies: Matt Lunning (UNMC) • BCT Lifetime Achievement Award Nursing program, hosted by Crystal Patterson: • Viral management around HCT/CAR-T: Elaine Courtney • Bispecifics in NHL: Kaitlin Kelly (UChicago) • Survivorship after allo-HCT & CAR-T: Hannah Butler • New FDA-approved BMT therapies: Emilie Aschenbrenner (Froedtert/MCW) 📍 Kosair for Kids CTR Building, 505 S. Hancock St. 🎓 Up to 5.5 AMA PRA Category 1 Credits™ | 6.6 nursing CE (full day), 3.3 (half day) Thank you to Rebecca Thurman, Elaine Courtney, Crystal Patterson & Brooke Whitlock, and to UofL Health and the University of Louisville. See you Saturday! #hemonc #bmtsm #uoflhealth

Loading… This year at #LHH26, we are introducing “ASH Sneak Peek.” I will highlight some of what to look for at the @ASH_hematology American Society of Hematology annual meeting. cmetracker.net/ULOU/Publishe…

It's that time of year again! 🩸 I'm delighted to invite you to the 4th Annual Louisville Hematology Highlights, a free, in-person CME event bringing together leading experts for a day of cutting-edge updates, lively debates, and multidisciplinary discussions on the latest in hematology. 📅 Saturday, November 7, 2026 📍 Louisville, KY This year, we're also hosting a parallel nursing symposium, so please bring your whole team. Great patient care is a team effort, and this event is designed with that in mind. Whether you're a physician, APP, nurse, pharmacist, or trainee, there's something here for you. I hope to see you there! 🔗 [Registration link] cmetracker.net/ULOU/Publishe… @awandoc @DrHKantarjian @hhashmi87 @Ramikomrokji @JohnPLeonardMD @lymphomaphilia @NicholasShortMD @MediHumdani #Hematology #CME #Oncology #CellTherapy #BoneMarrowTransplant #NursingEducation #Louisville #MedicalEducation

For the 6th year in a row the grant awards program open again. With 35 young physicians helped over the past 5years we look towards this program to continue to grow bigger. Please join me in supporting this cause!

My patient brought me this gift to her allogeneic stem cell transplant education session. I like it… – at Louisville, KY

We had the pleasure and honor hosting Dr. Usama Gergis the division chief of transplant and cellular therapy at @JeffersonUniv Thomas Jefferson University at our annual Lung Yam Memorial Lecture Departmnet of Medicine Grand Rounds @uofl @uoflmedschool

Join me this weekend for a lively case discussion this Sunday!

#NewProfilePic #ALF26